Implementation of business intelligence system in manufacturing enterprise

Poslovna inteligencija uzdiže informacije i znanje na višu razinu unutar poduzeća. Podaci i informacije postaju bit poslovanja u 21. stoljeću. Informacije su na dohvat ruke. Na temelju njih, i uz njihovu pomoć, ljudi donose odluke, usmjeravaju svoje aktivnosti, obavljaju svakodnevne poslove i zadatke, planiraju budućnost i rješavaju probleme. Informacije pretvorene u znanje nužne su i nezamjenjive na svakom području ljudskog života. Inteligentno poduzeće je ono koje brže donosi kvalitetnije odluke i nadmudruje svoje konkurente. Znači, cilj je biti brži i mudriji od konkurenta. Količina podataka i informacija se udvostručuje svake dvije godine i potrebno je znati dobro iskoristiti to na dinamičnom tržištu koje stalno traži promjene. Poslovna inteligencija postaje osnovno strateško usmjerenje poduzeća. Nove inovacije na tržištu poslovne inteligencije su pokazatelj koliko je poduzećima potrebna pomoć oko poslovanja. Ključ uspjeha u poslovanju poduzeća su suvremene informacijske tehnologije, poslovni informacijski sustavi te čovjek koji će uz njihovu pomoć odnositi odluke.Business intelligence takes information and knowledge to a higher level within the enterprise. Data and information are becoming the essence of business in the 21st century. The information is at your fingertips. Based on them and with their help, people make decisions, direct their activities, perform daily tasks and tasks, plan for the future and solve problems. Information transformed into knowledge is necessary and irreplaceable in every area of human life. An intelligent company is one that makes better decisions faster and outperforms its competitors. So the goal is to be faster and wiser than your competitor. The amount of data and information doubles every two years and you need to be able to make good use of it in a dynamic market that is constantly looking for change. Business intelligence is becoming a core strategic focus of businesses. New innovations in the business intelligence market are an indicator of how much business needs help with businesses. The key to success in business is modern information technology, business information systems and the person who will help them make decisions

Does the use of high dose atorvastatin in combination with dual antiplatelet therapy modify residual platelet activity in patients with acute coronary syndrome?

Introduction: Dual antiplatelet therapy (DAPT) represents one of the pillars in the treatment of acute coronary syndromes (ACS)1. In the past the most commonly used combination of antiplatelet drugs has been acetylsalicylic acid (ASA) and clopidogrel. Clopidogrel had a high incidence rate of high residual platelet reactivity and has, in recent years, been replaced with ticagrelor, a more potent platelet inhibitor with a more uniformed response across the patient population. The effect of high dose atorvastatin on platelet reactivity mediated by ASA and clopidogrel is well researched, however no studies have been published analyzing this effect when clopidogrel is substituted with ticagrelor. Purpose: To investigate if high dose atorvastatin modifies PF mediated by DAPT in patient with ACS as measured by platelet function tests (PFTs). Patients and Methods: We analyzed clinical characteristics and PF in patients presenting with ACS at the Department of Cardiovascular Diseases at the University Hospital Centre Zagreb from December 2015 to February 2018. Primary endpoint was PF after treatment with DAPT and/or high dose atorvastatin. We analyzed PF using the Multiplate platelet function analyzer. PFTs were performed 18-24 hours after therapy initiation. None of the patients were taking statins before the index event. Results: There were 35 patients with a mean (SD) age of 61.6 (12.2) years in the atorvastatin group and 29 patients with a mean (SD) of 62.6 (9.6) years in the no-atorvastatin group. Both groups were identical in all the baseline parameters except history of hyperlipidemia (34.5% vs 65.7%, P=0.023). There were no significant differences between the two groups in PF analyzed with PFTs (Figure 1). The difference in residual platelet reactivity remained non-significant even after adjusting for sex, age and hyperlipidemia as the only co-variate that was significantly different between the group (P=0.432). Conclusion: In this pilot study on a limited sample we found no difference in residual PF in patients on DAPT weather they are on treatment with high dose atorvastatin or not. These results show that the pleiotropic effects of atorvastatin on platelet reactivity are not significant in patients taking DAPT with ticagrelor and ASA. Acknowledgement: This pilot study was funded by Croatian Science Foundation

Effect of targeted temperature management on platelet function in patients with out-of-hospital cardiac arrest due to acute myocardial infarction

Introduction: Targeted temperature management (TTM) is recommended in the European Resuscitation Council Guidelines for Post-resuscitation Care.1 However, previous studies report controversial results on the effect of TTM on platelet function (PF) in patients on dual antiplatelet therapy (DAPT) with aspirin and P2Y12 inhibitors. Hypothesis: To assess if the effect of DAPT on platelet inhibition in patients undergoing TTM for out-of-hospital cardiac arrest (OHCA) is reduced compared to patients on the same therapy not undergoing this procedure. Patients and Methods: Clinical characteristics and PF were analyzed in 56 consecutive patients admitted to the Department of Cardiology at the University Hospital Centre between January 2012 and January 2019 under the diagnosis of acute myocardial infarction (AMI). Out of these 56 patients, 17 underwent TTM to 34°C (Intervention group) while the other 39 did not (Control group). Both groups received the loading dose of DAPT. We analyzed residual PF using the Multiplate® PF analyzer ADP test. Platelet function tests (PFT) were performed 18-24 hours after therapy initiation in both groups and 18-24 hours after return to normal body temperature of 36.5° C in the TTM group. The control group had an average temperature of 36.5° C at the time of the PFT. Results: There were 39 patients with a mean (SD) age of 63.2 (9.9) years in the Control group and 17 patients with a mean (SD) age of 58.6 (8.2) in the Interventional group. There were no significant differences in the baseline parameters between the groups (history of IHD, hyperlipidemia, diabetes mellitus, smoking, gender, prior medical therapy, current medical therapy). At the first time point (18-24 hours after initiating therapy) the intervention group had a significantly higher residual PF when compared to the control group (31.5 U vs 17.9 U; p<0.05). This difference is no longer present 18-24 hours after return to normothermia (p=0.2) (Figure 1). Conclusion: Our study shows that TTM decreases the effect of DAPT on PF in patients with AMI undergoing TTM for OHCA. This is in line with the findings published by Uminska et al2 who showed that TTM severely decreases the bioavailability of P2Y12 inhibitors in this group of patients. These findings indicate that patients with AMI who experienced an OHCA undergoing TTM could have an impaired response to standard DAPT

Diastolic function changes of the left and right ventricle after heart transplantation

Background: A new hemodynamic environment is set up after heart transplantation (HTx).1,2 Our aim was to assess changes in diastolic function of the left (LV) and right (RV) ventricle in HTx patients (Pts) during the 1st year and the influence of donor age, graft ischemic time (GIT) and acute right ventricular failure (ARVF). Patients and Methods: In 55 “healthy” HTx Pts echo was performed 1- and 12 months after HTx. Data on mitral valve (MV) E- (Ew) and A-wave velocity (Aw), MV and tricuspid (TV) E/A ratio, MV and TV E’ and A’ by tissue Doppler, septal E/E’, pulmonary vein diastolic velocity (PVd), systolic pulmonary pressure (sPAP), left atrial indexed volume (LAVI), right atrial pressure (RAP) were collected. Results: Ew significantly decreases during the 1st year (0.80 vs. 0.73 m/s; p=0.036) as well as E/E’ (11.5 vs. 9.1; p=0.009), PVd (0.67 vs. 0.55 m/s; p mean of 41 years) caused initially lower MV-E’ (r=-0.390, p=0.010) and higher sPAP (r=0.285; p=0.045). GIT had no influence on diastolic parameters. ARVF significantly correlated with lower TV-A’ acutely and after 1 year (ARVF 5 vs. no-ARVF 8 cm/s; r=-0.600, p= 0.011) and higher RAP (r=0.414, p=0.003). Conclusion: During the 1st postransplant year there is improvement in LA diastolic function with better early passive LV filling and reduction in PAH, without change in active filling phase or LA volume. In Pts with significant PAH mean E/E’ ratio within 1st month was 14, but after a year in Pts with persistent PAH it declines to only 10, preserving the higher E/A ratio. Higher donor age could impair the early LV ventricular filling with a trend toward more PAH but MV-E’ improves with time. ARVF reduces active RV filling (TV-A’) throughout the 1st year. GIT does not have influence on diastole

Implementation of business intelligence system in manufacturing enterprise

Poslovna inteligencija uzdiže informacije i znanje na višu razinu unutar poduzeća. Podaci i informacije postaju bit poslovanja u 21. stoljeću. Informacije su na dohvat ruke. Na temelju njih, i uz njihovu pomoć, ljudi donose odluke, usmjeravaju svoje aktivnosti, obavljaju svakodnevne poslove i zadatke, planiraju budućnost i rješavaju probleme. Informacije pretvorene u znanje nužne su i nezamjenjive na svakom području ljudskog života. Inteligentno poduzeće je ono koje brže donosi kvalitetnije odluke i nadmudruje svoje konkurente. Znači, cilj je biti brži i mudriji od konkurenta. Količina podataka i informacija se udvostručuje svake dvije godine i potrebno je znati dobro iskoristiti to na dinamičnom tržištu koje stalno traži promjene. Poslovna inteligencija postaje osnovno strateško usmjerenje poduzeća. Nove inovacije na tržištu poslovne inteligencije su pokazatelj koliko je poduzećima potrebna pomoć oko poslovanja. Ključ uspjeha u poslovanju poduzeća su suvremene informacijske tehnologije, poslovni informacijski sustavi te čovjek koji će uz njihovu pomoć odnositi odluke.Business intelligence takes information and knowledge to a higher level within the enterprise. Data and information are becoming the essence of business in the 21st century. The information is at your fingertips. Based on them and with their help, people make decisions, direct their activities, perform daily tasks and tasks, plan for the future and solve problems. Information transformed into knowledge is necessary and irreplaceable in every area of human life. An intelligent company is one that makes better decisions faster and outperforms its competitors. So the goal is to be faster and wiser than your competitor. The amount of data and information doubles every two years and you need to be able to make good use of it in a dynamic market that is constantly looking for change. Business intelligence is becoming a core strategic focus of businesses. New innovations in the business intelligence market are an indicator of how much business needs help with businesses. The key to success in business is modern information technology, business information systems and the person who will help them make decisions